RNS Number : 8230R
Avacta Group PLC
21 July 2025
Avacta Group plc
("Avacta" or the "Group" or the "Company")
Payment of Convertible Bond Installment
LONDON and PHILADELPHIA - 21 July 2025 - Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, confirms that further to the announcement of the £3.25m equity financing on 17 July 2025 (the "Placing"), it has settled the quarterly principal of £2.55 million and interest repayment of c.£0.414 million in respect of the Company's unsecured convertible bond in cash. The Placing is due to complete on 24 July 2025.
After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by £2.55 million to £22.95 million.
-Ends-
For further information from Avacta Group plc, please contact:
Avacta Group plc Michael Vinegrad, Group Communications Director
https://avacta.com/
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden
www.peelhunt.com
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert
Media Contact Carly Scaduto Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com
About Avacta - www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
About the pre|CISION® Platform
The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCVBLFLEDLBBBZ
